Valuation: Vivesto AB

Market Cap 99.2M 10.46M 9.05M 8.45M 7.77M 14.66M 995M 14.83M 38.89M 498M 39.29M 38.43M 1.66B P/E 2026 *
-2.93x
P/E 2027 * -2.14x
Enterprise Value 91.2M 9.62M 8.32M 7.77M 7.14M 13.48M 915M 13.63M 35.75M 458M 36.12M 35.33M 1.53B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
56.4%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Vivesto AB

Manager TitleAgeSince
Chief Executive Officer 68 23/01/2023
Director of Finance/CFO 55 01/07/2026
Chief Tech/Sci/R&D Officer 39 01/01/2023
Director TitleAgeSince
Chairman 46 25/05/2022
Director/Board Member 61 26/09/2019
Director/Board Member 43 25/05/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-99.00% - - 10.35M
+4.86%-4.16%+52.13%+160.26% 995B
+1.04%-3.43%+50.60%+52.38% 614B
+0.98%-6.46%+24.85%+66.66% 431B
+1.96%-0.87%+43.02%+37.60% 353B
-0.11%-4.56%+31.59%+39.73% 293B
+2.52%-6.99%+8.08%+10.32% 245B
+4.57%+3.75%+35.07%+67.64% 210B
-4.32%-12.25%-5.97%-44.56% 210B
-2.58%-1.91%+15.06%+67.46% 168B
Average +0.77%-5.02%+28.27%+50.83% 390.92B
Weighted average by Cap. +0.69%-5.89%+36.58%+75.03%

Financials

2026 *2027 *
Net sales - -
Net income -31M -3.27M -2.83M -2.64M -2.43M -4.58M -311M -4.63M -12.15M -156M -12.28M -12.01M -520M -46M -4.85M -4.2M -3.92M -3.6M -6.8M -461M -6.88M -18.03M -231M -18.22M -17.82M -771M
Net Debt -8M -844K -730K -682K -626K -1.18M -80.25M -1.2M -3.14M -40.2M -3.17M -3.1M -134M -10M -1.05M -913K -852K -783K -1.48M -100M -1.49M -3.92M -50.25M -3.96M -3.87M -168M
Logo Vivesto AB
Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.
Employees
4